Contineum Therapeutics Inc. (NASDAQ: CTNM ) shares are up on Friday as the company reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a potential treatment for chronic pain. The data released on Thursday focuses on patients for the non-opioid treatment of chronic osteoarthritis pain or chronic low back pain. CTNM PIPE-791 Phase 1b Trial Data The trial achieved its primary endpoint, demonstrating favorable safety and tolerability, with encouraging trends observed across multiple exploratory efficacy endpoints, including improvements in pain measures. The results support further evaluation of PIPE-791 for chronic pain treatment, reinforcing confidence in its potential. Contineum Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. Cash, cash equivalents, and marketable securities were $262.9 million as of December 31, 2025. Contineum believes its cash resources are sufficient ... Full story available on Benzinga.com
Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar
